Приложение 7 к Протоколу заочного голосования Организационного комитета Международной олимпиады Ассоциации «Глобальные университеты» для абитуриентов магистратуры и аспирантуры от 20.06.2023 № 1-з

**Структура научного профиля (портфолио) потенциальных научных руководителей участников трека аспирантуры Международной олимпиады Ассоциации «Глобальные университеты» для абитуриентов магистратуры и аспирантуры.**

|  |  |
| --- | --- |
| University | I.M. Sechenov First Moscow State Medical University (Sechenov University) |
| Level of English language proficiency | Fluency |
| The direction of training for which the graduate student will be accepted | 3.02 Clinical medicine, Oncology |
| Code of the field of study for which the graduate student will be accepted | Personalized Oncology (targeted drugs, immunoooncology) |
| List of research projects of a potential supervisor (participation/guidance) | Themes are developed within the framework of the scientific interest of the candidate and the supervisor |
| Research supervisor:  Marina I. Sekacheva,  Doctor of Science, Sechenov University | 3.02 Clinical medicine, Oncology  Personalized Oncology |
| Supervisor’s research interests:  Personalized Oncology (targeted drugs, immunooncology)  Pathology Genetics  Cancer prevention  Health Promotion Administration  Immunisation programmes (anti-cancer)  Life-long health management |
| Research highlights:  - 2009-2016: Scientific Secretary, Federal State Budgetary Scientific Institution “Petrovsky National Research Centre of Surgery” Moscow, Russia  - 2017-Present time: Head of the Institute for Personalized Oncology, Sechenov University  Areas of Expertise:  “Personalized Oncology is important for three reasons.  Firstly, cancer is a really life- threatening disease and has not just an effect on the quality of human life. Due to the diagnostic procedure on the early stages, we can save these people. Early diagnostics will allow cancer disease to fight simply.  Secondly, antitumor drugs have a large range of drug side effects. It is important to take into consideration the individual characteristics of each patient, to bring maximum benefit and cause minimum harm.  Thirdly, early diagnosis and optimization of treatment strategies will provide a significant burden reduction on the healthcare system. |
| Supervisor’s main publications: 19   * *RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer. Sorokin, M., Poddubskaya, E., Baranova, M., ...Sekacheva, M., Buzdin, A. Cold Spring Harbor Molecular Case Studies, 2020, 6(2), 4945* * *Quantification of Scheduling Impact on Safety and Efficacy Outcomes of Brain Metastasis Radio- and Immuno-Therapies: A Systematic Review and Meta-Analysis. Voronova, V., Lebedeva, S., Sekacheva, M., Helmlinger, G., Peskov, K. Frontiers in Oncology, 2020, 10,1609* * *Disparity between inter-patient molecular heterogeneity and repertoires of target drugs used for different types of cancer in clinical oncology* * *Zolotovskaia, M.A., Sorokin, M.I., Petrov, I.V., ... Sekacheva, M, Roumiantsev, S.A., Buzdin, A.A.International Journal of Molecular Sciences, 2020, 21(5), стр. 1–18, 1580*   *RNA sequencing for research and diagnostics in clinical oncology. Buzdin, A., Sorokin, M., Garazha, A., ... Sekacheva, M , Moshkovskii, S., Moiseev, A. Seminars in Cancer Biology, 2020, 60, стр. 311–323* |
| Results of intellectual activity: 6 patents   * Method for early diagnosis of lung cancer Patent for invention 2697971 from 21.08.2019 * System and method for screening determination of the probability of the presence of colorectal cancer Patent for invention 2698854 dated 08/30/2019 * Method for screening determination of the likelihood of bladder cancer. Patent for invention 2718272 dated 01.04.2020 * Method for screening determination of the likelihood of bladder cancer. Patent for invention 2718284 dated 01.04.2020 * Method and system for screening determination of the likelihood of lung cancer Eurasian patent 037137 dated 02/10/2021 * Method and system for screening determination of the likelihood of the presence of colorectal cancer Eurasian patent 037176 from 15.02.2021 |